Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2012: Simeprevir Safe and Effective for Hepatitis C Patients With Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 19 November 2012 00:00
- Written by Liz Highleyman
The HCV protease inhibitor simeprevir (formerly TMC435) is generally safe and well-tolerated in people with advanced liver fibrosis or cirrhosis, and improves sustained response rates when added to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last week in Boston. Related presentations showed that simeprevir is not implicated in drug-drug interactions with immunosuppressive agents or oral contraceptives.
AASLD 2012: Interferon-free Faldaprevir + BI 207127 Safe and Effective for Hepatitis C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Saturday, 17 November 2012 00:00
- Written by Keith Alcorn
The first major data on interferon-free hepatitis C treatment in people with cirrhosis shows that treatment using BI 201335 -- now known as faldaprevir -- and BI 207127 with ribavirin can be safe, and proved effective in up to 69% of patients, according to results from the SOUND-C2 study presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.
AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Liz Highleyman
A 12-week once-daily regimen of 2 direct-acting hepatitis C drugs -- sofosbuvir (formerly GS-7977) and daclatasvir (formerly BMS-790052) -- produced sustained virological response rates for treatment-naive patients in the 90% to 100% range, and appeared effective regardless of HCV subtype, IL28B pattern, or use of ribavirin, according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston. The developers are not planning further studies of this combination, however, leaving its fate uncertain. 
AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Liz Highleyman
The hepatitis C virus polymerase inhibitor sofosbuvir produces high rates of sustained virological response for genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data from the ELECTRON trial presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
AASLD 2012: Daclatasvir + Asunaprevir + BMS-791325 Cures Hard-to-treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 15 November 2012 00:00
- Written by Keith Alcorn
Twelve weeks of treatment with a 3-drug combination of new hepatitis C direct-acting antivirals that included neither pegylated interferon nor ribavirin led to sustained virological response 12 weeks after completion of treatment (SVR12) in up to 94% of previously untreated patients with hepatitis C genotype 1 in a preliminary Phase 2 trial with 16 patients, Gregory Everson from the University of Colorado reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
More Articles...
- AASLD 2012: Abbott Interferon-free Combination 'Promising' in Harder-to-treat People with Hep C
- AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Merck Will Soon Start 2 New Trials of MK-5172 in Interferon-free Hepatitis C Regimens
Web Design and Development by